HIKAL
Back to All Ratios
|
HIKAL Last 5 Year EV/EBIT History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
EV/EBIT(x) | 26.73 | 27.13 | 22.37 | 9.65 | 8.07 |
What is the latest EV/EBIT ratio of HIKAL ?
Year | EV/EBIT |
---|---|
Mar2024 | 26.73 |
Mar2023 | 27.13 |
Mar2022 | 22.37 |
Mar2021 | 9.65 |
Mar2020 | 8.07 |
How is EV/EBIT of HIKAL Trending?
Years | EV/EBIT | % Change | |
---|---|---|---|
Mar2024 | 26.73 | -1.47 | |
Mar2023 | 27.13 | 21.28 | |
Mar2022 | 22.37 | 131.81 | |
Mar2021 | 9.65 | 19.58 | |
Mar2020 | 8.07 | - |
Other Financial Ratios of HIKAL
Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Sales/Fixed Asset Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Receivable days Inventory Days Payable days | Valuation Parameters PER PCE Price/Book Yield EV/Net Sales EV/Core EBITDA EV/CE M Cap / Sales | Growth Ratios Net Sales Growth Core EBITDA Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Total Debt/Equity Current Ratio Quick Ratio Interest Cover Total Debt/Mcap |
Compare EV/EBIT ratio of peers of HIKAL
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
HIKAL | ₹5,435.1 Cr | 14.2% | 14.8% | 57% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹431,892.0 Cr | 3.7% | -3.2% | 46.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹166,129.0 Cr | 5.1% | 6.1% | 64% | Stock Analytics | |
CIPLA | ₹121,231.0 Cr | 0.6% | -3.7% | 26.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹101,431.0 Cr | 1.9% | -3.4% | 5.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹97,639.9 Cr | 2.3% | -3.4% | 54% | Stock Analytics |
HIKAL Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
HIKAL | 14.2% |
14.8% |
57% |
SENSEX | 0.9% |
2% |
21% |
You may also like the below Video Courses